{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:00:33Z","timestamp":1784656833677,"version":"3.55.0"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.2967\/jnumed.123.266537","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T20:40:15Z","timestamp":1699562415000},"page":"33-39","source":"Crossref","is-referenced-by-count":15,"title":["Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [<sup>68<\/sup>Ga]Ga-DOTA-CCK-66 PET\/CT in 2 Patients with Medullary Thyroid Cancer"],"prefix":"10.2967","volume":"65","author":[{"given":"Thomas","family":"G\u00fcnther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Holzleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Viering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roswitha","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgine","family":"Wienand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dierks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Pfob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Bundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Kircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"2024011701100700000_65.1.33.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01195-4"},{"key":"2024011701100700000_65.1.33.2","unstructured":"Thyroid cancer: statistics. Cancer.net website. https:\/\/www.cancer.net\/cancer-types\/thyroid-cancer\/statistics#:\u223c:text=In%202023%2C%20an%20estimated%2043%2C720,with%20thyroid%20cancer%20in%202020. Published August 2023. Accessed October 30, 2023."},{"key":"2024011701100700000_65.1.33.3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22244"},{"key":"2024011701100700000_65.1.33.4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3892\/ol.2010.223","article-title":"Medullary thyroid carcinoma: the third most common thyroid cancer reviewed","volume":"2","author":"Stamatakos","year":"2011","journal-title":"Oncol Lett."},{"key":"2024011701100700000_65.1.33.5","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0335"},{"key":"2024011701100700000_65.1.33.6","doi-asserted-by":"crossref","first-page":"17588359221101691","DOI":"10.1177\/17588359221101691","article-title":"RET kinase inhibitors for RET-altered thyroid cancers","volume":"14","author":"Vodopivec","year":"2022","journal-title":"Ther Adv Med Oncol."},{"key":"2024011701100700000_65.1.33.7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.beem.2017.04.009","article-title":"Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer","volume":"31","author":"Hadoux","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"2024011701100700000_65.1.33.8","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-815727"},{"key":"2024011701100700000_65.1.33.9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-39-3-487"},{"key":"2024011701100700000_65.1.33.10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","article-title":"EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma","volume":"47","author":"Giovanella","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024011701100700000_65.1.33.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-2031-6"},{"key":"2024011701100700000_65.1.33.12","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1245\/s10434-018-6829-3","article-title":"Medullary thyroid carcinoma: do ultrasonography and F-DOPA-PET-CT influence the initial surgical strategy?","volume":"25","author":"Brammen","year":"2018","journal-title":"Ann Surg Oncol."},{"key":"2024011701100700000_65.1.33.13","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1089\/thy.2018.0351","article-title":"F-18-dopa positron emission tomography\/computed tomography is more sensitive than whole-body magnetic resonance imaging for the localization of persistent\/recurrent disease of medullary thyroid cancer patients","volume":"29","author":"Terroir","year":"2019","journal-title":"Thyroid."},{"key":"2024011701100700000_65.1.33.14","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.3390\/cancers13225776","article-title":"Update on preclinical development and clinical translation of cholecystokinin-2 receptor targeting radiopharmaceuticals","volume":"13","author":"von Guggenberg","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2024011701100700000_65.1.33.15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/ph16020278","article-title":"Effects of side chain and peptide bond modifications on the targeting properties of stabilized minigastrin analogs","volume":"16","author":"Zavvar","year":"2023","journal-title":"Pharmaceuticals (Basel)."},{"key":"2024011701100700000_65.1.33.16","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/pharmaceutics15030796","article-title":"Effect of N-terminal peptide modifications on in\u00a0vitro and in\u00a0vivo properties of 177Lu-labeled peptide analogs targeting CCK2R","volume":"15","author":"H\u00f6rmann","year":"2023","journal-title":"Pharmaceutics."},{"key":"2024011701100700000_65.1.33.17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1021\/acsmedchemlett.0c00636","article-title":"1,5-disubstituted 1,2,3-triazoles as amide bond isosteres yield novel tumor-targeting minigastrin analogs","volume":"12","author":"Grob","year":"2021","journal-title":"ACS Med Chem Lett."},{"key":"2024011701100700000_65.1.33.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.207845"},{"key":"2024011701100700000_65.1.33.19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40658-022-00487-7","article-title":"Comparison of image quality and spatial resolution between 18F, 68Ga, and 64Cu phantom measurements using a digital Biograph Vision PET\/CT","volume":"9","author":"Braune","year":"2022","journal-title":"EJNMMI Phys."},{"key":"2024011701100700000_65.1.33.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1818-9"},{"key":"2024011701100700000_65.1.33.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.221283"},{"key":"2024011701100700000_65.1.33.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264977"},{"key":"2024011701100700000_65.1.33.23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13550-023-01016-y","article-title":"Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs","volume":"13","author":"Holzleitner","year":"2023","journal-title":"EJNMMI Res."},{"key":"2024011701100700000_65.1.33.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.progpolymsci.2005.09.004"},{"key":"2024011701100700000_65.1.33.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0803-4"},{"key":"2024011701100700000_65.1.33.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263323"},{"key":"2024011701100700000_65.1.33.27","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3390\/ph15121467","article-title":"Introduction of a SiFA moiety into the D-glutamate chain of DOTA-PP-F11N results in radiohybrid-based CCK-2R-targeted compounds with improved pharmacokinetics in\u00a0vivo","volume":"15","author":"Holzleitner","year":"2022","journal-title":"Pharmaceuticals (Basel)."},{"key":"2024011701100700000_65.1.33.28","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10494"},{"key":"2024011701100700000_65.1.33.29","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20059"},{"key":"2024011701100700000_65.1.33.30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/pharmaceutics15030826","article-title":"Development of the first 18F-labeled radiohybrid-based minigastrin derivative with high target affinity and tumor accumulation by substitution of the chelating moiety","volume":"15","author":"G\u00fcnther","year":"2023","journal-title":"Pharmaceutics."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.266537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T09:11:33Z","timestamp":1705482693000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.266537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,2]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.2967\/jnumed.123.266537"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.266537","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}